Minerva Neurosciences | NERV - Assets


Minerva Neurosciences reported $97.97M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Adma Biologics USD 665.18M 40.94M Mar/2026
ALKERMES USD 4.26B 1.77B Mar/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
AstraZeneca USD 114.02B 59M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Cipla INR 424.96B 23.32B Mar/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 156.57M 58.73M Dec/2025
CSL USD 37.9B 1.5B Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Grifols EUR 23.15B 142.7M Dec/2025
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Novavax USD 1.04B 133.35M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Takeda JPY 15.45T 44.34B Mar/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025